<DOC>
	<DOCNO>NCT01426373</DOCNO>
	<brief_summary>To evaluate safety deoxycholic acid subcutaneous injection submental area ( chin ) .</brief_summary>
	<brief_title>Open-Label Study Deoxycholic Acid Reduction Localized Subcutaneous Fat Submental Area</brief_title>
	<detailed_description />
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Submental fat grade investigator 2 , 3 , 4 use ClinicianReported Submental Fat Rating Scale ( CRSMFRS ) grade subject 2 , 3 , 4 use PatientReported Submental Fat Rating Scale ( PRSMFRS ) determine visit 1 ( within 28 day subject 's first dose session ) Dissatisfaction submental area rat subject 0 , 1 , 2 use Subject Selfrating Scale ( SSRS ) determine visit 1 ( within 28 day subject 's first dose session ) Males nonpregnant , nonlactating female 18 year age great , day subject 's first dosing session ( visit 2 ) . Females childbearing potential must negative human chorionic gonadotropin ( serum ) test result within 28 day visit 2 agree practice adequate contraception , judgment investigator , course study A normal result coagulation test ( prothrombin time ( PT ) , partial thromboplastin time ( PTT ) ) obtain within 28 day subject 's first dose session History stable body weight , judgment investigator , least 6 month subject 's first dosing session Expected understand comply visit schedule protocolspecified test procedure agreement subject refrain making significant change , judgment investigator , dietary exercise habit course subject 's participation Medically able undergo administration study drug determine clinical laboratory test obtain within 28 day subject 's first dosing session investigator identifies clinically significant abnormality Signed informed consent obtain studyspecific procedure perform History intervention treat submental fat ( eg , liposuction , surgery , lipolytic agent ) History trauma associate chin neck area , judgment investigator may affect evaluation safety efficacy treatment A grade 4 Submental Skin Laxity Grading scale ( SMSLG ) anatomical feature ( eg , predominant subplatysmal fat , loose skin neck chin area , prominent platysmal band ) reduction submental fat may , judgment investigator , result aesthetically unacceptable outcome Evidence cause enlargement submental area ( eg , thyroid enlargement , cervical adenopathy ) localize submental fat Body mass index ≥ 40 kg/m² determine visit 1 ( week 0 ) History current symptom dysphagia Any medical condition would interfere assessment safety efficacy compromise subject 's ability undergo study procedure give informed consent Treatment radio frequency , laser procedure , chemical peel , dermal filler neck chin area within 12 month first treatment session , botulinum toxin injection neck chin area within 6 month first treatment session History sensitivity component study drug topical local anesthetic ( eg , lidocaine , benzocaine , novocaine ) Previous treatment study previous participation Kytherasponsored ATX101 study Treatment investigational device agent within 30 day subject 's first treatment session</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>